Effects of postoperative osteoporosis treatment on subsequent fracture and the 5-year survival rates after hemiarthroplasty for hip fracture
- 88 Downloads
According to the literature, only 20–30% of patients are screened for osteoporosis after a hip fracture. Osteoporosis treatment may have a potential protective effect on the 5-year mortality rate. Our results demonstrated that 5-year survival is higher in patients who received osteoporosis treatment after hemiarthroplasty for hip fracture compared with those who did not.
This study aims to investigate the status of osteoporosis treatment in patients who underwent hemiarthroplasty for an osteoporotic hip fracture and to compare subsequent fractures and the 5-year survival rates of these patients with those who did not receive the osteoporosis treatment.
Patients > 65 years of age who underwent hemiarthroplasty for an osteoporotic hip fracture were included in this retrospective multicenter study. Patients who died within 12 months postoperative, who were lost to follow-up, and those with malignancy and secondary osteoporosis were excluded. Group I comprised patients who had no postoperative osteoporosis screening and treatment, and Group II comprised those who received the screening and treatment.
A total of 460 of 562 patients (82%) did not receive osteoporosis treatment after hip fracture. No significant difference was observed between the groups in terms of subsequent fracture numbers and fracture sites (p = 0.296 and 0.240, respectively). Mean 5-year survival rate was significantly higher in Group II (p = 0.002).
According to our results, elderly patients who underwent hemiarthroplasty for an osteoporotic hip fracture were not commonly screened or treated for osteoporosis. Our results demonstrated no significant difference between the groups in terms of subsequent fracture. However, we observed a significant high 5-year survival rate among patients who received the osteoporosis treatment.
KeywordsOsteoporosis Hip fracture Hemiarthroplasty Mortality Survival
Compliance with ethical standards
This retrospective multicenter study was performed with the approval of an institutional ethical review board and in accordance with the Declaration of Helsinki.
Conflict of interest
- 4.Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152(6):380–390. https://doi.org/10.7326/0003-4819-152-6-201003160-00008 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Hallberg I, Bachrach-Lindström M, Hammerby S, Toss G, Ek AC (2009) Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study. BMC Musculoskelet Disord 10:135. https://doi.org/10.1186/1471-2474-10-135
- 13.Mugnier B, Daumas A, Couderc AL, Mizzi B, González T, Amrani A, Lévêque P, Aymes B, Argenson JN, Villani P (2018) Clinical effectiveness of osteoporosis treatment in older patients: a fracture liaison service-based prospective study. J Women Aging 8:1–13. https://doi.org/10.1080/08952841.2018.1529473 CrossRefGoogle Scholar
- 14.Nurmi-Lüthje I, Sund R, Juntunen M, Lüthje P (2011) Post-hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: a nationwide study in Finland. J Bone Miner Res 26(8):1845–1853. https://doi.org/10.1002/jbmr.375 CrossRefPubMedGoogle Scholar
- 17.Friedman SM, Mendelson DA, Kates SL, McCann RM (2008) Geriatric co-management of proximal femur fractures: total quality management and protocol-driven care result in better outcomes for a frail patient population. J Am Geriatr Soc 56(7):1349–1356. https://doi.org/10.1111/j.1532-5415.2008.01770.x CrossRefPubMedGoogle Scholar
- 18.Bukata SV, Digiovanni BF, Friedman SM, Hoyen H, Kates A, Kates SL, Mears SC, Mendelson DA, Serna FH Jr, Sieber FE, Tyler WK (2011) A guide to improving the care of patients with fragility fractures. Geriatr Orthop Surg Rehabil 2(1):5–37. https://doi.org/10.1177/2151458510397504 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Kim SC, Kim MS, Sanfélix-Gimeno G, Song HJ, Liu J, Hurtado I, Peiró S, Lee J, Choi NK, Park BJ, Avorn J (2015) Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med 128(5):519–526.e1. https://doi.org/10.1016/j.amjmed.2015.01.014 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Desai RJ, Mahesri M, Abdia Y, Barberio J, Tong A, Zhang D, Mavros P, Kim SC, Franklin JM (2018) Association of osteoporosis medication use after hip fracture with prevention of subsequent nonvertebral fractures: an instrumental variable analysis. JAMA Netw Open 1(3):e180826. https://doi.org/10.1001/jamanetworkopen.2018.0826 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Degli Esposti L, Girardi A, Saragoni S, Sella S, Andretta M, Rossini M, Giannini S; on the behalf of the Study group (2018) Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk. Endocrine https://doi.org/10.1007/s12020-018-1824-9, 64, 367, 377CrossRefGoogle Scholar
- 27.Su FM, Chen YC, Cheng TT, Lin WC, Lui CC (2015) Is raloxifene associated with lower risk of mortality in postmenopausal women with vertebral fractures after vertebroplasty?: a hospital-based analysis. BMC Musculoskelet Disord 16:209–205. https://doi.org/10.1186/s12891-015-0670-7 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.van Geel TACM, Bliuc D, Geusens PPM, Center JR, Dinant GJ, Tran T, van den Bergh JPW, McLellan AR, Eisman JA (2018) Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: a prospective cohort study. PLoS One 13(6):e0198006. https://doi.org/10.1371/journal.pone.0198006 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809. https://doi.org/10.1056/NEJMoa074941 CrossRefPubMedGoogle Scholar